• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

来自海洋链霉菌TPU1236A的抗分枝杆菌核苷类抗生素。

Anti-mycobacterial nucleoside antibiotics from a marine-derived Streptomyces sp. TPU1236A.

作者信息

Bu Ying-Yue, Yamazaki Hiroyuki, Ukai Kazuyo, Namikoshi Michio

机构信息

Faculty of Pharmaceutical Sciences, Tohoku Pharmaceutical University, Aoba-ku, Sendai 981-8558, Japan.

出版信息

Mar Drugs. 2014 Dec 17;12(12):6102-12. doi: 10.3390/md12126102.

DOI:10.3390/md12126102
PMID:25522318
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4278220/
Abstract

Five new nucleoside antibiotics, named streptcytosines A-E (1-5), and six known compounds, de-amosaminyl-cytosamine (6), plicacetin (7), bamicetin (8), amicetin (9), collismycin B (10), and SF2738 C (11), were isolated from a culture broth of Streptomyces sp. TPU1236A collected in Okinawa, Japan. The structures of new compounds were elucidated on the basis of their spectroscopic data (HRFABMS, IR, UV, and 2D NMR experiments including 1H-1H COSY, HMQC, HMBC, and NOESY spectra). Streptcytosine A (1) belonged to the amicetin group antibiotics, and streptcytosines B-E (2-5) were derivatives of de-amosaminyl-cytosamine (6), 2,3,6-trideoxyglucopyranosyl cytosine. Compound 1 inhibited the growth of Mycobacterium smegmatis (MIC = 32 µg/mL), while compounds 2-5 were not active at 50 µg/disc. Bamicetin (8) and amicetin (9) showed the MICs of 16 and 8 µg/mL, respectively.

摘要

从日本冲绳采集的链霉菌属TPU1236A的培养液中分离出5种新的核苷类抗生素,命名为链霉菌胞嘧啶A - E(1 - 5),以及6种已知化合物,去氨基氨甲酰胞嘧啶(6)、plicacetin(7)、巴米霉素(8)、阿米西丁(9)、柱晶白霉素B(10)和SF2738 C(11)。根据新化合物的光谱数据(高分辨快原子轰击质谱、红外光谱、紫外光谱以及二维核磁共振实验,包括1H - 1H COSY、HMQC、HMBC和NOESY谱)阐明了它们的结构。链霉菌胞嘧啶A(1)属于阿米西丁类抗生素,链霉菌胞嘧啶B - E(2 - 5)是去氨基氨甲酰胞嘧啶(6)、2,3,6 - 三脱氧葡萄糖吡喃糖基胞嘧啶的衍生物。化合物1抑制耻垢分枝杆菌的生长(最小抑菌浓度 = 32 μg/mL),而化合物2 - 5在50 μg/圆片时无活性。巴米霉素(8)和阿米西丁(9)的最小抑菌浓度分别为16和8 μg/mL。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/4278220/c680289b65f6/marinedrugs-12-06102-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/4278220/2629ad0ab51e/marinedrugs-12-06102-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/4278220/0c5f83026a98/marinedrugs-12-06102-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/4278220/597637857f1a/marinedrugs-12-06102-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/4278220/c680289b65f6/marinedrugs-12-06102-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/4278220/2629ad0ab51e/marinedrugs-12-06102-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/4278220/0c5f83026a98/marinedrugs-12-06102-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/4278220/597637857f1a/marinedrugs-12-06102-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e343/4278220/c680289b65f6/marinedrugs-12-06102-g004.jpg

相似文献

1
Anti-mycobacterial nucleoside antibiotics from a marine-derived Streptomyces sp. TPU1236A.来自海洋链霉菌TPU1236A的抗分枝杆菌核苷类抗生素。
Mar Drugs. 2014 Dec 17;12(12):6102-12. doi: 10.3390/md12126102.
2
High Plasticity of the Amicetin Biosynthetic Pathway in sp. SHP 22-7 Led to the Discovery of Streptcytosine P and Cytosaminomycins F and G and Facilitated the Production of 12F-Plicacetin.链霉菌 SHP 22-7 中的安密西林生物合成途径具有高可塑性,由此发现了链丝菌素 P、胞嘧啶氨基霉素 F 和 G,并促进了 12F-plicacetin 的生产。
J Nat Prod. 2022 Mar 25;85(3):530-539. doi: 10.1021/acs.jnatprod.1c01051. Epub 2022 Mar 9.
3
Lemnalosides A-D, decalin-type bicyclic diterpene glycosides from the marine soft coral Lemnalia sp.莱姆纳糖苷A-D,来自海洋软珊瑚莱姆纳属物种的十氢化萘型双环二萜糖苷
J Nat Prod. 2007 Jun;70(6):901-5. doi: 10.1021/np0603424. Epub 2007 May 17.
4
Generation by mutasynthesis of potential neuroprotectant derivatives of the bipyridyl collismycin A.通过突变合成潜在神经保护剂衍生物的双吡啶型 collismycin A。
Bioorg Med Chem Lett. 2013 Oct 15;23(20):5707-9. doi: 10.1016/j.bmcl.2013.08.017. Epub 2013 Aug 12.
5
Antibacterial Muraymycins from Mutant Strains of Streptomyces sp. NRRL 30471.链霉菌 NRRL 30471 突变株来源的抗菌 Muraymycins。
J Nat Prod. 2018 Apr 27;81(4):942-948. doi: 10.1021/acs.jnatprod.7b01054. Epub 2018 Mar 19.
6
Cytotoxic bipyridines from the marine-derived actinomycete Actinoalloteichus cyanogriseus WH1-2216-6.海洋来源放线菌 Actinoalloteichus cyanogriseus WH1-2216-6 中的细胞毒性联吡啶。
J Nat Prod. 2011 Aug 26;74(8):1751-6. doi: 10.1021/np200258h. Epub 2011 Jul 19.
7
Cytosine-type nucleosides from marine-derived Streptomyces rochei 06CM016.来自海洋来源的罗氏链霉菌06CM016的胞嘧啶型核苷。
J Antibiot (Tokyo). 2016 Jan;69(1):51-6. doi: 10.1038/ja.2015.72. Epub 2015 Jul 1.
8
Isolation and structure elucidation of the nucleoside antibiotic strepturidin from Streptomyces albus DSM 40763.从白色链霉菌DSM 40763中分离核苷类抗生素链脲苷并阐明其结构
J Antibiot (Tokyo). 2014 Jun;67(6):471-7. doi: 10.1038/ja.2014.16. Epub 2014 Mar 5.
9
Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.5-烷基(或卤代)-3'-取代嘧啶核苷类似物的抗分枝杆菌活性。
Bioorg Med Chem Lett. 2012 Jan 15;22(2):1091-4. doi: 10.1016/j.bmcl.2011.11.114. Epub 2011 Dec 4.
10
Two new compounds from a marine-derived Streptomyces sp.从海洋来源的链霉菌属中分离出的两种新化合物
J Asian Nat Prod Res. 2017 Dec;19(12):1172-1176. doi: 10.1080/10286020.2017.1307189. Epub 2017 Apr 1.

引用本文的文献

1
Harnessing Actinobacteria secondary metabolites for tuberculosis drug discovery: Historical trends, current status and future outlooks.利用放线菌次生代谢产物进行结核病药物发现:历史趋势、现状与未来展望。
Nat Prod Bioprospect. 2025 Aug 11;15(1):52. doi: 10.1007/s13659-025-00533-8.
2
Diversity of secondary metabolites from marine Streptomyces with potential anti-tubercular activity: a review.具有潜在抗结核活性的海洋链霉菌次级代谢产物的多样性:综述
Arch Microbiol. 2025 Feb 17;207(3):64. doi: 10.1007/s00203-024-04233-8.
3
Mavintramycin A is a promising antibiotic for treating complex infectious disease.

本文引用的文献

1
Delamanid: A new armor in combating drug-resistant tuberculosis.地拉米定:对抗耐药结核病的新武器。
J Pharmacol Pharmacother. 2014 Jul;5(3):222-4. doi: 10.4103/0976-500X.136121.
2
Trends in discovery of new drugs for tuberculosis therapy.结核病治疗新药的发现趋势。
J Antibiot (Tokyo). 2014 Sep;67(9):655-9. doi: 10.1038/ja.2014.109. Epub 2014 Aug 6.
3
Perspectives on tuberculosis pathogenesis and discovery of anti- tubercular drugs.结核病发病机制及抗结核药物发现的研究视角
马文他霉素 A 是一种很有前途的抗生素,可用于治疗复杂的传染病。
Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0091723. doi: 10.1128/aac.00917-23. Epub 2024 Feb 9.
4
Purification and biological analysis of antimicrobial compound produced by an endophytic Streptomyces sp.一株内生链霉菌产生的抗菌化合物的纯化及生物学分析
Sci Rep. 2023 Sep 14;13(1):15248. doi: 10.1038/s41598-023-41296-x.
5
The intriguing chemistry and biology of sulfur-containing natural products from marine microorganisms (1987-2020).海洋微生物含硫天然产物的有趣化学与生物学研究(1987 - 2020年)
Mar Life Sci Technol. 2021 May 19;3(4):488-518. doi: 10.1007/s42995-021-00101-2. eCollection 2021 Nov.
6
A Novel Finding: 2,4-Di-tert-butylphenol from Streptomyces bacillaris ANS2 Effective Against Mycobacterium tuberculosis and Cancer Cell Lines.一项新发现:来自枯草芽孢杆菌 ANS2 的 2,4-二叔丁基苯酚可有效对抗结核分枝杆菌和癌细胞系。
Appl Biochem Biotechnol. 2023 Nov;195(11):6572-6585. doi: 10.1007/s12010-023-04403-2. Epub 2023 Mar 7.
7
Exploration of marine natural resources in Indonesia and development of efficient strategies for the production of microbial halogenated metabolites.探索印度尼西亚的海洋自然资源和开发高效策略以生产微生物卤代代谢物。
J Nat Med. 2022 Jan;76(1):1-19. doi: 10.1007/s11418-021-01557-3. Epub 2021 Aug 20.
8
Mining Indonesian Microbial Biodiversity for Novel Natural Compounds by a Combined Genome Mining and Molecular Networking Approach.通过组合基因组挖掘和分子网络方法挖掘印度尼西亚微生物生物多样性中的新型天然化合物。
Mar Drugs. 2021 May 28;19(6):316. doi: 10.3390/md19060316.
9
Identification and characterization of enzymes involved in the biosynthesis of pyrimidine nucleoside antibiotics.鉴定和表征嘧啶核苷抗生素生物合成中的酶。
Nat Prod Rep. 2021 Jul 21;38(7):1362-1407. doi: 10.1039/d0np00064g.
10
Antimicrobial compounds from marine actinomycetes.海洋放线菌来源的抗菌化合物。
Arch Pharm Res. 2020 Jul;43(7):677-704. doi: 10.1007/s12272-020-01251-0. Epub 2020 Jul 20.
Curr Med Chem. 2014;21(30):3466-77. doi: 10.2174/0929867321666140706144933.
4
Delamanid: first global approval.德拉马尼:全球首次批准。
Drugs. 2014 Jun;74(9):1041-5. doi: 10.1007/s40265-014-0241-5.
5
Characterizing amosamine biosynthesis in amicetin reveals AmiG as a reversible retaining glycosyltransferase.阐明阿米卡星中阿莫沙胺的生物合成途径,揭示 AmiG 为一种可逆的保留型糖基转移酶。
J Am Chem Soc. 2013 Aug 21;135(33):12152-5. doi: 10.1021/ja401016e. Epub 2013 Aug 9.
6
Tuberculosis.肺结核
N Engl J Med. 2013 Feb 21;368(8):745-55. doi: 10.1056/NEJMra1200894.
7
Calpinactam, a new anti-mycobacterial agent, produced by Mortierella alpina FKI-4905.卡尔平他胺,一种新的抗分枝杆菌药物,由高山被孢霉 FKI-4905 产生。
J Antibiot (Tokyo). 2010 Apr;63(4):183-6. doi: 10.1038/ja.2010.14. Epub 2010 Feb 26.
8
NMR structure of the peptidyl transferase RNA inhibitor antibiotic amicetin.肽基转移酶RNA抑制剂抗生素阿霉素的核磁共振结构。
Magn Reson Chem. 2007 Feb;45(2):133-41. doi: 10.1002/mrc.1932.
9
The paper disc method for determination of bacterial sensitivity to antibiotics. Studies on the accuracy of the technique.用于测定细菌对抗生素敏感性的纸片法。该技术准确性的研究。
Scand J Clin Lab Invest. 1960;12(4):408-13. doi: 10.3109/00365516009065405.
10
The global situation of MDR-TB.耐多药结核病的全球形势。
Tuberculosis (Edinb). 2003;83(1-3):44-51. doi: 10.1016/s1472-9792(02)00058-6.